Search Results - "Miserachs, N"

MON-PP150: Nutritional Parameters and Outcomes in Non Critically Ill Patients with Parenteral Nutrition: Elderly Versus Younger Patients by Berlana, D, Mateu De Antonio, J, Pons Busom, M, Badia Tahull, M.B, Miana Mena, M.T, Sunyer Esquerrà, N, Murgadella Sancho, A, Martínez Bernabe, E, Miserachs, N, Sanmartin, M

Get full text

Remote pharmaceutical care for patients with rheumatoid arthritis and psoriasis by Martínez-Santana, V., Boix-Montañés, A., Fernández-Cañabate, E., González-Melarde, B., Miserachs-Aranda, N., Modamio-Charles, P., Fernández-Lastra, C., Mariño-Hernández, E.

“…Background Access to drugs with hospital-restricted dispensation, such as those for patients with rheumatoid arthritis or psoriasis, is regulated by healthcare…”
Get full text

Home enteral nutrition in Spain; NADYA registry 2011-2012 by Wanden-Berghe, Carmina, Matía Martín, P, Luengo Pérez, L M, Cuerda Compes, C, Burgos Peláez, R, Alvarez Hernández, J, Calleja Fernández, A, Pérez de la Cruz, A, Gómez Candela, C, Leyes García, P, Laborda González, L, Martínez Olmos, M A, Campos Martín, C, Suárez Llanos, J P, Penacho Lázaro, M A, Gonzalo Marín, M, Salas Salvadó, J, Irles Rocamora, J A, Cánovas Gaillemin, B, Carrero Caballero, M C, Moreno Villares, J M, Garde Orbaiz, C, Miserachs Aranda, N, Del Olmo García, M D, Apezetxea Celaya, A, Mauri, S

“…To describe the results of the home enteral nutrition (HEN) registry of the NADYA-SENPE group in 2011 and 2012. We retrieved the data of the patients recorded…”
Get full text

Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain by Grau, Santiago, Fondevilla, Esther, Echeverría-Esnal, Daniel, Alcorta, Amaia, Limon, Enric, Gudiol, Francesc

“…Abstract Introduction The overall increase in the use of carbapenems could lead to the selection of carbapenem-resistant bacteria. The objectives of this study…”
Get full text

Registro del grupo nadya-senpe de nutrición enteral domiciliaria en españa; años 2016 y 2017 by Wanden-berghe Lozano, Carmina

Get full text

Identification of a novel single-nucleotide polymorphism (Val554Ile) and definition of eight common alleles for human IL4RA exon 11 by Lozano, F., Places, L., Vilà, J.-M., Padilla, O., Arman, M., Gimferrer, I., Suárez, B., López de la Iglesia, A., Miserachs, N., Vives, J.

“…: The interleukin (IL)‐4 receptor α chain gene (IL4RA) is a polymorphic gene which is reportedly involved in the development of atopy. Of the 14…”
Get full text

Nosocomial Infections in Spain: Results of Five Nationwide Serial Prevalence Surveys (EPINE Project, 1990 to 1994) by Vaqué, Josep, Rosselló, José, Trilla, Antoni, Monge, Vicente, García-Caballero, Juan, Arribas, José L., Blasco, Pedro, Sáenz-Domínguez, José R., Albero, Inma, Calbo, Francisco, Barrio, Josep, Herruzo, Rafael, Sáenz-González, Carmen, Arévalo, José M.

“…Objective: To determine trends in rates of nosocomial infections in Spanish hospitals. Design: Prospective prevalence studies, performed yearly from 1990…”
Get full text

Drotrecogin alfa (activated): specific treatment for serious sepsis by Miserachs Aranda, N, Soy Muner, D, Codina Jané, C, Ribas Sala, J

“…Severe sepsis is a high prevalent disease at Intensive Care Units with no specific treatment till recently. Several clinical trials show low serum levels of…”
Get full text

Rupture of trilucent-type breast implants: A clinical case by ALCARAZ, Juan Ballesta, DOMINGUEZ, Enrique Delgado, BUSQUESTS, Nuria Miserachs, CANTO, Vicente Ros

“…We present the case of a patient who underwent cosmetic breast augmentation in 1996, with Trilucent-type implants. Four years later, there were delayed…”
Get full text

Drotrecogin alfa (activated): specific treatment for serious sepsis by Miserachs Aranda, N, Soy Muner, D, Codina Jané, C, Ribas Sala, J

Get full text

Drotrecogina alfa (activada): tratamiento específico para la sepsis grave by Miserachs Aranda, N., Soy Muner, D., Codina Jané, C., Ribas Sala, J.

“…La sepsis grave es una patología de elevada prevalencia en las unidades de cuidados intensivos sin un tratamiento específico hasta hace poco. En diferentes…”
Get full text